Author Archives: Lu Rahman

#Clinical specialities #Clinical trials #Drug repositioning #Parkinson's

Cancer anti-sickness drug offers hope for Parkinson’s hallucinations

A double-blind clinical trial, will investigate if a drug used to treat nausea in chemotherapy patients, could alleviate hallucinations in people with Parkinson’s. Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, is partnering with UCL, and investing £1 million in a pioneering Phase II clinical trial to… Read More

#Editor's Choice #News

#Autoimmune disease #Cancer

Tapping a staggering market potential

Dr Michael Shepard and Sir Marc Feldmann, Enosi Life Sciences, examine the benefits of distinguishing between TNF receptors. Siloed thought processes are potentially costing the pharmaceutical industry billions of dollars per year. One particularly interesting case is that of autoimmune diseases and cancer. These two areas of medicine have a… Read More

#Exclusive Content

#Drug candidates #Drug discovery

BioIVT kit aids liver toxicity and inflammation studies for drug discovery research

BioIVT has launched the HEPATOMUNE kit, a long-term, stable, in vitro model for evaluating immune-related and inflammation-mediated liver injury. Hepatomune cultures are composed of hepatocytes, stromal cells and Kupffer cells in a tri-culture, mimicking the physiological microenvironment of the liver, and providing an optimal model for studying cytokines and cytokine… Read More

#News

#Assay development optimisation & technology #Covid-19 #Therapeutics

PerkinElmer immunoassay helps identify therapeutic compounds to tackle COVID-19

A research team at the National Center for Advancing Translational Sciences (NCATS), an arm of the National Institutes of Health (NIH), is working with PerkinElmer’s AlphaLISA immunoassay to help support the global search for effective COVID-19 therapeutics. The NCATS research project is focused on studying small molecule drug compounds that… Read More

#Covid-19 #News

#Covid-19 #Drug development #Therapeutics

Aerogen collaborates on development of COVID-19 inhaled therapies

Aerogen has released details of a collaborative effort to support global pharmaceutical companies developing COVID-19 vaccines and therapies. To date, more than ten million patients globally have been treated safely and effectively with Aerogen’s drug delivery technology. As the global scientific community rallies against the pandemic, there has been interest… Read More

#Covid-19 #News

#CAR-T #Immunotherapy #Oncology

Collaboration aims to develop targeted, effective cancer immunotherapies

Immunai has joined forces with Baylor College of Medicine to bring more targeted and effective cancer therapies to market. Leveraging Immunai’s single-cell technology and artificial intelligence, Baylor and Immunai will analyse natural killer T (NKT) cells and genetically engineer them into immunotherapies that target a variety of cancers, including solid… Read More

#News

#Ingredients / APIs / Fine chemicals

New chemical safety platform helps prevent lab accidents

CAS and the Pistoia Alliance, a global non-profit that works to lower barriers to innovation in life science and healthcare R&D, have launched a new Pistoia Alliance Chemical Safety Library platform. This resource aims to mitigate the serious risks researchers working with potentially hazardous chemicals face due to unanticipated chemical… Read More

#News

#Drug discovery #Screening

CU Anschutz announces technology to cut drug screening time in half

Author Julia Milzer, CU Anschutz  The CU Skaggs School of Pharmacy and Pharmaceutical Sciences at CU Anschutz has announced a new drug discovery technology that can cut the screening time for new drug therapies by half. It will enable rapid and cost-effective screening of hundreds of thousands of potential therapies… Read More

#News

Live-Cell Analysis Training Video: From Culture to Assay

Cell-based assay research in pharma and academia, depends on forms of measurement of living cells. As soon as cells are placed in culture, there is opportunity to learn about or monitor the cells prior to analysis. Live-Cell Analysis enables real-time analysis with full cell tracking workflows.

#Resources

#Covid-19 #Immunology / Virology & Vaccines

UK government signs deal to help speed up COVID-19 vaccine

hVIVO, has signed a contract with the UK government to develop a COVID-19 (SARS-CoV-2) human challenge study model. The model development involves the manufacture of the challenge virus and the first-in-human characterisation study for this virus. The contract starts immediately and could be worth approximately £10 million to hVIVO –… Read More

#Covid-19 #News

#AMR #Antibiotics #Laboratory of the Future

Analytica virtual conference: new approaches in the fight against antibiotic resistance

The Analytica conference accompanies Analytica 2020, which is currently taking place virtually until 23 October. Key topics in focus at the event are  antibiotic resistance and the ‘laboratory of the future’. The number of microbes that are resistant to certain classes of antibiotics is increasing – hampering therapy. Humans and… Read More

#News

#Biologics / Biotechnology #CAR-T

Are you interested in reversing the state of T cell exhaustion?

If you are a biotech scientist interested in reversing or overcoming the state of T-cell exhaustion, this webinar will show you how advanced flow cytometry can be used to effectively evaluate immuno-oncology drugs using physiologically relevant assays. Quantifying T cell exhaustion: An insight into BiTE antibodies and CAR-T cells for improved… Read More

#News